Mesothelioma Related Clinical Trials:
Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma

Article Tools:

In Page Navigation: - General Info - Purpose - Eligibility - Contacts & Locations - Additional Information

   

Status: Active
Sponsors and Collaborators: British Thoracic Society, Medical Research Council
Information provided by: National Cancer Institute (NCI)
Government Identifier: NCT00030459

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: mitomycin C; Drug: vinblastine; Drug: vinorelbine ditartrate; Procedure: chemotherapy

    - Return To Top

Purpose:


RATIONALE: Palliative therapy may help patients with advanced cancer live more comfortably. It is not yet known if palliative therapy is more effective with or without chemotherapy in treating patients who have malignant mesothelioma.

PURPOSE: Randomized phase II trial to compare the effectiveness of palliative therapy with or without different chemotherapy regimens in treating patients who have malignant mesothelioma.

Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Official Title: Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: November 2000

Detailed Description:

OBJECTIVES:

  • Determine the feasibility of palliative therapy alone versus palliative therapy with mitomycin, vinblastine, and cisplatin versus palliative therapy with vinorelbine in patients with malignant mesothelioma.
  • Determine the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of three treatment arms.

  • Arm I: Patients receive palliative therapy alone comprising non-chemotherapeutic therapy (e.g., radiotherapy, painkillers, steroids, relaxants, and special pain relief techniques).
  • Arm II: Patients receive palliative therapy as in arm I and chemotherapy comprising mitomycin IV (courses 1, 2, and 4 only), vinblastine IV, and cisplatin IV over 4 hours on day 1. Chemotherapy repeats every 21 days for a total of 4 courses.
  • Arm III: Patients receive palliative therapy as in arm I and chemotherapy comprising vinorelbine IV over 5 minutes once weekly on weeks 1-6 and 9-14.

Quality of life is assessed at baseline for all patients; at weeks 3, 6, 9, and 12 for arm I; at weeks 4, 7, 10, and 13 for arm II; at weeks 3, 6, 10, and 13 for arm III; at weeks 21 and 29, and then every 8 weeks thereafter for all patients.

Patients are followed every 8 weeks.

PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this study within 1 year.

    - Return To Top

Eligibility:

Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

DISEASE CHARACTERISTICS:

  • Immunohistochemically or cytologically confirmed malignant mesothelioma

    • Epithelial and other histological types
  • Symptomatic pleural effusion allowed if treated and controlled by drainage, pleurodesis, or pleurectomy
  • Prior surgical resection allowed if stable or progressive disease by 2 CT scan measurements at least 6 weeks apart

PATIENT CHARACTERISTICS:

Age:

  • Not specified

Performance status:

  • WHO 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC greater than 3,000/mm3
  • Neutrophil count greater than 1,500/mm3
  • Platelet count greater than 100,000/mm3

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • Considered medically fit to receive chemotherapy
  • No other disease or prior malignancy that would preclude study
  • No clinical evidence of infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior chemotherapy for mesothelioma

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • See Disease Characteristics

    - Return To Top

Contacts and Locations:

Please refer to this study by its ClinicalTrials.gov identifier: NCT00030459
Locations
United Kingdom
Dorothy House Foundation
Bradford-Onavon, United Kingdom, BA15 2LE
St. Peters Hospital
Chertsey Surrey, United Kingdom, KT 16 OPZ
United Kingdom, England
Leeds Teaching Hospital Trust
Leeds, England, United Kingdom, LS1 3EX
Medical Research Council Clinical Trials Unit
London, England, United Kingdom, NW1 2DA
Princess Royal Hospital
Hull, England, United Kingdom, HU8 9HE
Royal Marsden Hospital
Sutton, England, United Kingdom, SM2 5PT
Saint Bartholomew's Hospital
London, England, United Kingdom, EC1A 7BE
United Kingdom, Scotland
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Stobhill General Hospital
Glasgow, Scotland, United Kingdom, G21 3UW

Sponsors and Collaborators
British Thoracic Society
Medical Research Council

Investigators
Study Chair: Martin F. Muers, MD Leeds General Infirmary
Study Chair: David J. Girling, MD Medical Research Council

    - Return To Top

Additional Information:

Study ID Numbers: CDR0000069167, BTS-MESO-1, MRC-BTS-MESO-1, EU-20134
First Received: February 14, 2002
Last Updated: February 9, 2008
ClinicalTrials.gov Identifier: NCT00030459
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
localized malignant mesothelioma
advanced malignant mesothelioma
recurrent malignant mesothelioma

Study placed in the following topic categories:
Vinorelbine
Cisplatin
Mitomycin
Mesothelioma
Vinblastine
Mitomycins
Adenoma
Recurrence
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Mesothelioma
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Neoplasms, Mesothelial
Antineoplastic Agents
Mitosis Modulators
Physiological Effects of Drugs
Enzyme Inhibitors
Antimitotic Agents
Antibiotics, Antineoplastic
Pharmacologic Actions
Neoplasms
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Antineoplastic Agents, Phytogenic
Alkylating Agents
Nucleic Acid Synthesis Inhibitors

    - Return To Top

Free case consultation

If you or a loved one has been diagnosed with mesothelioma or another asbestos-related disease, contact us using the form below to speak with a mesothelioma consultant, free of charge.